US Executive Compensation Proxy SEC Filings — May 04, 2026

04-05-2026

National Vision Holdings, Inc. reported strong FY2025 financial performance with net revenue up 9.0% to $1,987.5 million, Adjusted Operating Income rising to $102.5 million from $65.5 million in FY2024 (Adjusted Operating Margin expanding 5.2 percentage points to 8.8% from 3.6%), and Adjusted Diluted EPS increasing to $0.80 from $0.52. Comparable store sales grew 5.9% (Adjusted 6.0%), while overall store count growth was flat at 0.8% to 1,250 stores. The proxy statement seeks stockholder approval for election of 11 director nominees, say-on-pay, and ratification of Deloitte & Touche LLP as auditors for 2026, ahead of the June 17, 2026 Annual Meeting.

• ·Annual Meeting scheduled for June 17, 2026 at 1:00 p.m. ET in Alpharetta, Georgia; record date April 20, 2026.
• ·Eleven director nominees proposed for election.
• ·Financial results reflect continuing operations; Legacy segment and majority of AC Lens treated as discontinued.

04-05-2026

Imunon, Inc. (IMNN) filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders on June 16, 2026, at 10:00 a.m. ET virtually, with a record date of April 17, 2026, and 3,983,342 shares of common stock outstanding. Shareholders will vote on Proposal 1 (election of Class I directors by plurality), Proposal 2 (ratification of WithumSmith+Brown PC as independent auditors for the year ending December 31, 2026), Proposal 3 (non-binding advisory approval of 2025 Named Executive Officer compensation), and Proposal 4 (amendment to the 2018 Stock Incentive Plan). No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Voting methods: internet at www.proxyvote.com, phone, proxy card, or live webcast at www.virtualshareholdermeeting.com/IMNN2026 using 16-digit control number
• ·Broker non-votes expected only on Proposal 2 (routine); non-routine for Proposals 1, 3, 4
• ·2025 Annual Report on Form 10-K available at www.sec.gov or www.imunon.com

04-05-2026

Wellgistics Health, Inc. seeks shareholder approval for three proposals at a special meeting: (1) changing the company name to Vantix Health Inc. with potential ticker 'MEDS', (2) authorizing 10,000,000 shares of blank check preferred stock for financial flexibility, and (3) amending the Incentive Plan to add 56,493,936 shares (45% of outstanding common stock) plus annual increases up to 10%. While these aim to support growth and strategy as a micro health ecosystem, the preferred stock authorization could dilute existing shareholders, reduce voting power, and enable anti-takeover measures. The Board unanimously recommends approval of all proposals, with no immediate impact on current stockholders' rights.

• ·No dissenters’ rights for any proposal under Delaware General Corporation Law.
• ·Affirmative vote of majority of outstanding common stock required for each proposal.
• ·Name change effective upon filing Certificate of Amendment with Delaware Secretary of State; existing stock certificates remain valid.
• ·No current plans to issue preferred stock or specific designations.
• ·Incentive Plan Administrator has discretion on actual annual increases.

04-05-2026

PagerDuty, Inc.'s 2026 Proxy Statement outlines the virtual Annual Meeting on June 18, 2026, seeking approval to elect four Class I directors (Donald J. Carty, Sarah Franklin, William Losch, Jennifer Tejada) for terms expiring in 2029, ratify PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending January 31, 2027, and an advisory vote on named executive officer compensation. The Board comprises 10 members (90% independent, 60% female, average tenure 4.5 years), with all current directors attending the prior year's meeting. No performance metrics or changes are detailed in the provided content.

• ·Record Date: April 20, 2026
• ·Annual Meeting: June 18, 2026 at 2:00 p.m. Pacific Time via www.virtualshareholdermeeting.com/PD2026
• ·Fiscal year ended January 31, 2026 (Form 10-K referenced)
• ·Board attendance: All current directors attended 2025 Annual Meeting

04-05-2026

STAAR Surgical's 2026 proxy statement solicits votes for electing seven directors (Neal C. Bradsher, Arthur C. Butcher, Wei Jiang, Richard T. LeBuhn, Louis E. Silverman, Christopher M. Wang, Lilian Y. Zhou), amending the equity incentive plan to add 3.9 million shares, ratifying BDO USA, P.C. as auditors, and advisory approval of executive compensation at the June 18, 2026 virtual annual meeting. Following a challenging 2025 marked by slower revenue growth, elevated costs, reduced profitability, and rejection of the Alcon merger in January 2026, the company reports positive momentum with EVO+ launch in China exceeding expectations, surpassing 4 million Implantable Collamer Lenses sold globally in February 2026, and expanded regulatory indications. Interim Co-CEOs outline 2026 priorities for revenue growth, profitability improvement, and innovation acceleration amid new board additions representing over 37% of shares.

• ·Annual meeting on June 18, 2026 at 8:30 a.m. PT via www.virtualshareholdermeeting.com/STAA2026; record date April 20, 2026
• ·US FDA expanded EVO age indication to 21-60; Brazil expanded to -0.5D to -6.0D; Taiwan approval early 2025
• ·Fiscal year ended January 2, 2026

04-05-2026

Virco Mfg. Corporation's proxy statement for the 2026 Annual Meeting on June 16, 2026, seeks stockholder approval for electing two Class I directors, an advisory vote on Named Executive Officers' compensation (Say-on-Pay), and ratification of Baker Tilly US, LLP as independent auditors for fiscal year 2027. The record date is April 24, 2026, with 15,729,543 shares of common stock outstanding, entitling holders to one vote per share (cumulative for directors). No financial performance metrics or changes are detailed in the provided filing content.

• ·Annual Meeting location: 2027 Harpers Way, Torrance, CA 90501 at 10:00 a.m. Pacific Time.
• ·Quorum requires majority of voting power present in person or by proxy.
• ·Brokers may only vote on Proposal 3 (auditor ratification) without instructions.

04-05-2026

Helios Technologies, Inc. (HLIO) filed its 2026 Proxy Statement (DEF 14A) on May 04, 2026, disclosing details on executive compensation for Principal Executive Officer (PEO) Josef Matosevic and other named executive officers (NEOs), including equity awards granted, vested, and changes in fair value across fiscal years ending 2023, 2024, and January 3, 2026. The filing outlines robust governance policies such as an enhanced Clawback Policy adopted in 2023, Insider Trading Policy prohibiting hedging, Human Rights Policy, Conflict Minerals Policy, and Code of Conduct for Suppliers. It also details cybersecurity measures using the CIS Top 18 framework, monthly employee training, penetration testing, and commitments to sustainability and customer-focused innovations without highlighting any governance shortcomings.

• ·Fiscal year ended January 3, 2026
• ·Clawback Policy applies to current and former executive officers with a three-year recovery period for incentive-based compensation in case of accounting restatements
• ·Cybersecurity strategy includes CIS Top 18 framework, multi-factor authentication, Zero Trust principles, and penetration tests across all subsidiaries

04-05-2026

Xos, Inc. has filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 23, 2026, seeking approval for electing three Class II directors, ratifying Grant Thornton LLP as auditors for FY 2026, amending the 2021 Equity Incentive Plan to increase reserved shares, advisory approval of FY 2025 named executive officer compensation, frequency of future say-on-pay votes (recommending 1 year), and authorizing issuance of 20% or more of outstanding common stock upon conversion of certain promissory notes at potentially below Nasdaq minimum prices, which could result in a change of control. As of the April 24, 2026 record date, 12,056,211 shares of common stock were issued and outstanding. No financial performance metrics or period-over-period changes are disclosed in the filing.

• ·Annual Meeting at 11:00 a.m. Pacific Daylight Savings Time via www.virtualshareholdermeeting.com/XOS2026.
• ·Record date: close of business on April 24, 2026.
• ·Stockholder list available for examination starting June 13, 2026 at company headquarters.

04-05-2026

RH's DEF 14A proxy statement for the 2026 Annual Meeting of Shareholders on June 18, 2026, at 10:30 a.m. PT seeks to elect three director nominees, approve named executive officer compensation on an advisory basis, vote on the frequency of future such votes (Board recommends one year), and ratify PricewaterhouseCoopers LLP as independent auditors for fiscal 2026 ending January 30, 2027. The record date is April 21, 2026, with 18,900,769 shares of common stock outstanding entitled to vote. No financial performance data or period-over-period comparisons are provided in this governance-focused filing.

• ·Fiscal 2025 Annual Report on Form 10-K filed with SEC on April 1, 2026.
• ·Proxy materials available online at www.proxyvote.com.
• ·Shareholder list available for inspection 10 days prior to meeting by contacting Corporate Secretary at (415) 924-1005.

04-05-2026

Veeva Systems Inc. is holding its 2026 Annual Meeting of Shareholders on June 17, 2026, virtually, to elect nine director nominees and ratify KPMG LLP as independent auditors for the fiscal year ending January 31, 2027. The Board highlights strong shareholder engagement, reaching out to holders of 40% of shares and meeting with 30%, leading to actions like a $2 billion share repurchase program, commitment to annual say-on-pay votes, and discussions on CEO compensation and director independence. The Board composition features an average age of 62, tenure of 9.3 years, 22% female directors, and 22% from underrepresented communities, with all nominees except CEO Peter Gassner deemed independent.

• ·Record Date: April 20, 2026
• ·Annual Meeting: June 17, 2026, 9:00 a.m. Pacific Time, virtual at www.virtualshareholdermeeting.com/VEEV2026
• ·Voting for directors: Majority of votes duly cast (for > against) per nominee
• ·Voting for auditor ratification: Majority of votes duly cast (for > against)
• ·Fiscal year end referenced: January 31, 2026 (past), January 31, 2027 (future)